Analyst Charles Zhu from LifeSci Capital maintained a Buy rating on IDEAYA Biosciences and keeping the price target at $62.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Charles Zhu has given his Buy rating due to a combination of factors that underscore IDEAYA’s expanding precision oncology platform and disciplined capital deployment. He views the first-patient dosing of IDE892, a next-generation PRMT5 inhibitor engineered for synergy with MAT2A agent IDE397, as a key value driver, citing its differentiated chemistry and pharmacologic profile relative to other candidates in development.
In his assessment, the strategic choice to scale back the MAT2A plus Trodelvy program and reallocate resources toward wholly owned MTAP-deletion assets and potential Topo ADC combinations enhances both focus and economic upside. He also highlights the upcoming Phase 2b/3 OptiMUM-02 data in metastatic uveal melanoma as a near-term catalyst, with the company’s roughly four years of cash runway providing sufficient funding to advance these programs through important inflection points.
According to TipRanks, Zhu is a 5-star analyst with an average return of 25.0% and a 62.84% success rate. Zhu covers the Healthcare sector, focusing on stocks such as Revolution Medicines, IDEAYA Biosciences, and Crescent Biopharma.
In another report released today, Mizuho Securities also reiterated a Buy rating on the stock with a $46.00 price target.